Please specify if you are a UK healthcare professional, a UK resident prescribed
 (dupilumab) or a member of the public.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you get any side effects, talk to your healthcare professional. You can also report side effects directly via the Yellow Card Scheme at:  or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.


Sanofi and Regeneron are collaborating in a global development programme and commercialisation for Dupixent.
Copyright © 2022 Aventis Pharma Limited. All rights reserved.

MAT-GB-2102758(v4.0) | Date of preparation: April 2022